Amgen Inc. (AMGN)
NMS · Drug Manufacturers - General
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Peers in Drug Manufacturers - General
All in industry →Eli Lilly and Company
Johnson & Johnson
AbbVie Inc.
AstraZeneca PLC
Merck & Co., Inc.
Novartis AG
Gilead Sciences, Inc.
Novo Nordisk A/S
Pfizer Inc.
Bristol-Myers Squibb Company
Recent press releases
April 2026
Amgen reports 10% revenue growth, funds R&D, and returns $5 billion dividend
# 🧾 What This Document Is 📑 This filing is a Definitive Additional Materials supporting Amgen’s annual proxy statement. Think of a proxy statement as a comprehensive guide and required disclosure package mailed to shareholders before the company's Annual Meeting of Stockholders. 👉 This document
Amgen Vote on Executive Pay and Independent Chairman Proposal
# 🧾 What This Document Is This is a **DEF 14A**, also called a "proxy statement." It's a formal document sent to a company's shareholders ahead of an annual meeting. Its job is to give shareholders the information they need to vote on important company matters. 👉 In simple terms: This is Amgen's
SEC filings
All filings →Insider trades
All insider trades →Amgen Inc. has no reported insider trades in the last 90 days.